Identifying the factors underlying discontinuation of triptans

Headache

Volumn 54, Issue 2, 2014, Pages 278-289

  Wells, Rebecca E ^a   Markowitz, Shira Y ^b   Baron, Eric P ^c   Hentz, Joseph G ^f   Kalidas, Kavita ^d   Mathew, Paul G ^e   Halker, Rashmi ^f   Dodick, David W ^f   Schwedt, Todd J ^f  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b LANIADO HOSPITAL   (Israel)

^c Department of Clinical Pathology Leveland Clinic   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

^f MAYO CLINIC   (United States)

Author keywords

adherence; discontinuation; migraine; treatment; triptan

Indexed keywords

ADHERENCE; DISCONTINUATION; MIGRAINE; TREATMENT; TRIPTAN;

ADULT; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; DEPRESSION; DISABILITY EVALUATION; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT COMPLIANCE; RISK FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPTAMINES; WITHHOLDING TREATMENT;

EID: 84893937469     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12198     Document Type: Article

References (12)

1. Silberstein SD,. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the quality standards subcommittee of the American Academy of Neurology. Neurology. 2000; 55: 754-762.
2. MacGregor EA, Brandes J, Eikermann A,. Migraine prevalence and treatment patterns: The global migraine and zolmitriptan evaluation survey. Headache. 2003; 43: 19-26.
3. Holland S, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB,. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. J Neurol Sci. 2013; 326: 10-17.
4. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF,. Migraine diagnosis and treatment: Results from the American migraine study II. Headache. 2001; 41: 638-645.
5. Linde M, Jonsson P, Hedenrud T,. Influence of disease features on adherence to prophylactic migraine medication. Acta Neurol Scand. 2008; 118: 367-372.
6. Mulleners WM, Whitmarsh TE, Steiner TJ,. Noncompliance may render migraine prophylaxis useless, but once-daily regimens are better. Cephalalgia. 1998; 18: 52-56.
7. Packar RC, O'Connell P,. Medication compliance among headache patients. Headache. 1986; 26: 416-419.
8. Blumenfeld AM, Bloudek LM, Becker WJ, et al. Patterns of use and reasons for discontinuation of prophylactic medications for episodic migraine and chronic migraine: Results from the second international burden of migraine study (IBMS-II). Headache. 2013; 53: 644-655.
9. Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME,. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache. 2004; 44: 661-668.
10. Holland S, Fanning KM, Serrano D, Buse DC, Reed ML, Lipton RB,. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: Results from the American Migraine Prevalence and Prevention (AMPP) study. J Neurol Sci. 2013; 7: 10-17.
11. Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK,. Predictors of adherence to triptans: Factors of sustained vs lapsed users. Headache. 2009; 49: 386-394.
12. Ho TW, Rodgers A, Bigal ME,. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis. Headache. 2009; 49: 395-403.